Literature DB >> 9749797

Reduction of noradrenaline impairs attention and dopamine depletion slows responses in Parkinson's disease.

M Riekkinen1, K Kejonen, P Jäkälä, H Soininen, P Riekkinen.   

Abstract

We investigated the role dopamine and noradrenaline in the modulation of attention in Parkinson's disease (PD) patients. We observed that PD patients with mild and moderate motor disability did not differ in their attentional accuracy in easy tests, but the severe PD group was slightly disrupted in a more arduous test of attention. Attentional accuracy was not affected by withdrawal of dopaminergic drugs in mild or severe PD patients. The movements of severe PD patients were slower, and withdrawal of dopaminergic drugs aggravated motor slowing more in severe PD patients. Clonidine (0.5 and 2 microg/kg) retarded accuracy of performance in the most difficult attention test in mild PD patients, but had no effect in the severe PD group. Clonidine had no effect on movement times. These data suggest that a defect in noradrenaline release may contribute to the impaired accuracy of attention in severe PD patients and that dopamine may be important for maintaining rapid motor responding.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9749797     DOI: 10.1046/j.1460-9568.1998.00145.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  13 in total

1.  Influence of noradrenaline denervation on MPTP-induced deficits in mice.

Authors:  T Archer; A Fredriksson
Journal:  J Neural Transm (Vienna)       Date:  2005-12-16       Impact factor: 3.575

2.  Restoration and putative protection in Parkinsonism.

Authors:  T Archer; A Fredriksson
Journal:  Neurotox Res       Date:  2000       Impact factor: 3.911

3.  Postnatal iron overload destroys NA-DA functional interactions.

Authors:  A Fredriksson; T Archer
Journal:  J Neural Transm (Vienna)       Date:  2006-08-24       Impact factor: 3.575

4.  Brain catecholamine alterations and pathological features with aging in Parkinson disease model rat induced by Japanese encephalitis virus.

Authors:  N Hamaue; A Ogata; M Terado; K Ohno; S Kikuchi; H Sasaki; K Tashiro; M Hirafuji; M Minami
Journal:  Neurochem Res       Date:  2006-11-14       Impact factor: 3.996

5.  Effects of clonidine and alpha-adrenoceptor antagonists on motor activity in DSP4-treated mice II: interactions with apomorphine.

Authors:  A Fredriksson; T Archer
Journal:  Neurotox Res       Date:  2000-04       Impact factor: 3.911

6.  Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: a pilot open-label study.

Authors:  Laura Marsh; Kevin Biglan; Melissa Gerstenhaber; James R Williams
Journal:  Mov Disord       Date:  2009-01-30       Impact factor: 10.338

7.  Noradrenaline and Parkinson's disease.

Authors:  Claire Delaville; Philippe De Deurwaerdère; Abdelhamid Benazzouz
Journal:  Front Syst Neurosci       Date:  2011-05-18

8.  APOE4 exacerbates α-synuclein pathology and related toxicity independent of amyloid.

Authors:  Na Zhao; Olivia N Attrebi; Yingxue Ren; Wenhui Qiao; Berkiye Sonustun; Yuka A Martens; Axel D Meneses; Fuyao Li; Francis Shue; Jiaying Zheng; Alexandra J Van Ingelgom; Mary D Davis; Aishe Kurti; Joshua A Knight; Cynthia Linares; Yixing Chen; Marion Delenclos; Chia-Chen Liu; John D Fryer; Yan W Asmann; Pamela J McLean; Dennis W Dickson; Owen A Ross; Guojun Bu
Journal:  Sci Transl Med       Date:  2020-02-05       Impact factor: 19.319

9.  Is DOPA-Responsive Hypokinesia Responsible for Bimanual Coordination Deficits in Parkinson's Disease?

Authors:  Quincy J Almeida; Matt J N Brown
Journal:  Front Neurol       Date:  2013-07-19       Impact factor: 4.003

10.  Dopaminergic, serotonergic, and noradrenergic deficits in Parkinson disease.

Authors:  Chandana Buddhala; Susan K Loftin; Brandon M Kuley; Nigel J Cairns; Meghan C Campbell; Joel S Perlmutter; Paul T Kotzbauer
Journal:  Ann Clin Transl Neurol       Date:  2015-09-12       Impact factor: 4.511

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.